BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31858758)

  • 41. Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
    Higgins L; Nasr SH; Said SM; Kapoor P; Dingli D; King RL; Rajkumar SV; Kyle RA; Kourelis T; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Ansell SM; Gonsalves WI; Thompson CA; Fervenza FC; Zand L; Hwa YL; Jevremovic D; Shi M; Leung N
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1037-1046. PubMed ID: 29848505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case.
    Beech C; Kumar D; Hendrickson J; Perincheri S; Tormey C; Bahar B
    Lab Med; 2019 Jul; 50(3):313-319. PubMed ID: 30657960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
    Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
    Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
    Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of plasma cells in Waldenström macroglobulinaemia.
    El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
    Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
    Jalali S; Ansell SM
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
    Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
    Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mast cells (MC) excess in a bone marrow (BM) associated with lymphoplasmacytic cells (LPC) in a 55-Y-old patient with Waldenström's macroglobulinemia (WM).
    Gentelet M; Demulder A
    Ann Biol Clin (Paris); 2021 Feb; 79(1):92-93. PubMed ID: 33527905
    [No Abstract]   [Full Text] [Related]  

  • 49. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
    Lin P; Medeiros LJ
    Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature.
    Nayak HK; Kar P; Bagchi A; Kapoor N; Kapahtia S; Sonika U; Kumar N; Kumar S
    JOP; 2013 Jan; 14(1):92-5. PubMed ID: 23306344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis].
    Debus J; Lemaire P; Alani M; Farhi J; Rose J; Cussac V; Defasque S; Denizon N; Ghnaya H; Besançon-Bergelin A; Laribi K; Pineau-Vincent F
    Ann Biol Clin (Paris); 2018 Aug; 76(4):451-457. PubMed ID: 30078781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia.
    Gnemmi V; Leleu X; Provot F; Moulonguet F; Buob D
    Am J Kidney Dis; 2012 Sep; 60(3):487-91. PubMed ID: 22721930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.
    Kyle RA; Larson DR; McPhail ED; Therneau TM; Dispenzieri A; Kumar S; Kapoor P; Cerhan JR; Rajkumar SV
    Mayo Clin Proc; 2018 Jun; 93(6):739-746. PubMed ID: 29656787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
    Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The epidemiology of Waldenström macroglobulinemia.
    McMaster ML
    Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
    Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
    Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
    Wang W; Lin P
    Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.
    de Tute RM; Rawstron AC; Owen RG
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):211-3. PubMed ID: 23523273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
    Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.